BUZZ-Myriad Genetics falls after preliminary Q4 revenue misses estimates
** Shares of medical test kit maker Myriad Genetics MYGN.O fall ~3% to $13.27
** MYGN says it expects Q4 rev. to be between $209 mln and $211 mln, below analyst estimates of $212.9 mln - data compiled by LSEG
** Co expects Q4 adj. EPS to be between 3 cents and 4 cents vs. analyst est. of 3 cents
** Co forecasts 2025 rev. to be between $840 mln and $860 mln below analyst est. of $876.7 mln
** Co forecasts 2025 adj. EPS to be between 7 cents and 11 cents vs. analyst est. of 8 cents
** 6 of 16 brokerages rate the stock "buy" or higher, 6 "hold" and 4 "sell" or lower; their median PT is $20.50 - LSEG
** MYGN fell 27.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available